Akoustis Technologies Azioni (NASDAQ: AKTS)

Ultime notizie per Akoustis Technologies (NASDAQ:AKTS) Azioni

Akoustis Technologies

Akoustis Technologies Inc is an emerging commercial product company focused on developing, designing, and manufacturing innovative RF filter solutions for the wireless industry, including for products such as smartphones and tablets, network infrastructure equipment, WiFi Customer Premise Equipment and defense applications. The company has developed a proprietary microelectromechanical system based bulk acoustic wave technology and a unique manufacturing process flow, called XBAW, for filters produced for use in RFFE modules. The company derives revenue from the sale of filter products under individual customer purchase orders, some of which have underlying master sales agreements that specify terms governing the product sales.

Akoustis Technologies, Inc. - Common Stock

Akoustis Technologies Inc

WIIM

RARE

Ultragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est

<p><strong>Share Repurchase Program:</strong></p>
<p>The Company's board of directors (the "Board") has approved a new share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company is authorized to repurchase up to $100.0 million in shares of the Company's common stock, inclusive of fees and commissions. This program replaces the Company's previous share repurchase program adopted in 2021, under which $9.4 million remained available for repurchase. The 2024 Share Repurchase Program is effective immediately and does not have an expiration date.</p>
<p>Repurchases under the 2024 Share Repurchase Program may be made, from time to time, in amounts and prices the Company deems appropriate and may be made pursuant to a trading plan intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Repurchases by the Company under the 2024 Share Repurchase Program will be subject to general market and economic conditions, applicable legal requirements and other considerations. The 2024 Share Repurchase Program may be suspended, modified or discontinued by the Board at any time without prior notice at the Company's discretion.</p>


News

Buybacks

Grocery Outlet Holding Corp. Has Approved A New Share Repurchase Program Pursuant To Which The Company Is Authorized To Repurchase Up To $100M In Shares Of The Company's Common Stock,

<p>Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $3.221 billion which Beat the analyst consensus estimate. This is a 11.54 percent decrease over sales of $3.64 billion the same period last year.</p>


Earnings

Earnings Misses

LUMN

Lumen Technologies Q3 2024 Adj EPS $(0.13) Misses $(0.09) Estimate, Sales $3.221B Beat $3.218B Estimate

<p>Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.18) by 144.44 percent.  The company reported quarterly sales of $854.000 thousand which missed the analyst consensus estimate of $6.477 million by 86.81 percent.  This is a 24.85 percent increase over sales of $684.000 thousand the same period last year.</p>


EOSE

Eos Energy Enterprises Q3 2024 Adj. EPS $(0.44) Misses $(0.18) Estimate, Sales $854.000K Miss $6.477M Estimate

<p>Momentum investing is all about the idea of following a stock&#39;s recent trend, which can be in either direction. In the &#39;long&#39; context, investors will essentially be &quot;buying high, but hoping to sell even higher.&quot; And for investors following this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.</p>
<p>Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the <a href="https://www.zacks.com/education/stock-style-scores/momentum-trading" target="_blank">Zacks Style Scores</a>, helps address this issue for us.</p>
<p>Below, we take a look at <strong>U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>)</strong>, which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.</p>
<p>It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. U.S. Bancorp currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.</p>
<h3>Set to Beat the Market?</h3>
<p>In order to see if USB is a promising momentum pick, let&#39;s examine some Momentum Style elements to see if this company holds up.</p>
<p>Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.</p>
<p>For USB, shares are up 0.21% over the past week while the Zacks Banks - Major Regional industry is up 0.33% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 6.12% compares favorably with the industry&#39;s 4.51% performance as well.</p>
<p>While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of U.S. Bancorp have risen 13.79%, and are up 33.8% in the last year. On the other hand, the S&amp;P 500 has only moved 7.29% and 32.85%, respectively.</p>
<p>Investors should also pay attention to USB&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. USB is currently averaging 8,694,755 shares for the last 20 days.</p>
<h3>Earnings Outlook</h3>
<p>The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with USB.</p>
<p>Over the past two months, 6 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost USB&#39;s consensus estimate, increasing from $3.86 to $3.92 in the past 60 days. Looking at the next fiscal year, 8 estimates have moved upwards while there have been 1 downward revision in the same time period.</p>
<h3>Bottom Line</h3>
<p>Given these factors, it shouldn&#39;t be surprising that USB is a #2 (Buy) stock and boasts a Momentum Score of B. If you&#39;re looking for a fresh pick that&#39;s set to soar in the near-term, make sure to keep U.S. Bancorp on your short list.</p>
<p><a href="https://www.zacks.com/stock/news/2364640/u-s-bancorp-usb-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2364640">To read this article on Zacks.com click here.</a></p>
<p><a href="https://www.zacks.com/">Zacks Investment Research</a></p>


Markets

Trading Ideas

General

U.S. Bancorp Is A Great Momentum Stock: Should You Buy?

Contracts

Eos Energy Announced A New Agreement With City Utilities To Provide 216 MWh Of Energy Storage For Two Project Sites In Missouri: Terms Not Disclosed

<p>National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) sees Q4 sales of $82.000 million-86.000 million vs $89.27 million estimate.</p>


Guidance

NCMI

National CineMedia Sees Q4 Sales $82.000M-86.000M vs $89.27M Est.

<p><strong>Outlook:</strong></p>
<p>The Company is updating key guidance figures for fiscal 2024 as follows:</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>Previous</td>
<td>Current</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New store openings, net(2)</td>
<td>62 to 64</td>
<td>66</td>
</tr>
<tr>
<td>Net sales</td>
<td>$4.30 billion to $4.35 billion</td>
<td>slightly above $4.35 billion</td>
</tr>
<tr>
<td>Comparable store sales increase</td>
<td>~3.5%</td>
<td>~2.4%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>~30.5%</td>
<td>~30.4%</td>
</tr>
<tr>
<td>Adjusted EBITDA(1)</td>
<td>$252 million to $260 million</td>
<td>$237 million to $242 million</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share(1)</td>
<td>$0.89 to $0.95</td>
<td>$0.77 to $0.80</td>
</tr>
<tr>
<td>Capital expenditures (net of tenant improvement allowances)</td>
<td>~$200 million</td>
<td>~$200 million</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Grocery Outlet Holding Corp. Updates FY24 EPS Guidance From $0.89-$0.95 To $0.77-$0.80 Vs $0.88 Est.; Revenue From $4.30B-$4.35B To Slightly Above $4.35B Vs $4.37B Est.

<p>Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) reported quarterly earnings of $0.02 per share. This is a 230.77 percent increase over losses of $(0.01) per share from the same period last year.  The company reported quarterly sales of $56.00 million which missed the analyst consensus estimate of $57.30 million by 2.28 percent.  This is a 10.60 percent increase over sales of $50.63 million the same period last year.</p>


VTEX

Vtex Q3 EPS $0.02 Up From $(0.01) YoY, Sales $56.00M Miss $57.30M Estimate

<p>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.53) by 8.5 percent.  The company reported quarterly sales of $139.494 million which beat the analyst consensus estimate of $135.794 million by 2.72 percent.  This is a 42.27 percent increase over sales of $98.052 million the same period last year.</p>


Earnings Beats

Ultragenyx Pharmaceutical Q3 2024 GAAP EPS $(1.40) Beats $(1.53) Estimate, Sales $139.494M Beat $135.794M Estimate

<p>United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.33 by 145.45 percent.  The company reported quarterly sales of $322.964 million which beat the analyst consensus estimate of $306.800 million by 5.27 percent.  This is a 17.89 percent increase over sales of $273.955 million the same period last year.</p>


UFCS

United Fire Gr Q3 2024 Adj. EPS $0.81 Beats $0.33 Estimate, Sales $322.964M Beat $306.800M Estimate

<p>On a day when global attention focused on the U.S. presidential election, Israeli Prime Minister <strong>Benjamin Netanyahu </strong>announced the dismissal of defense minister <strong>Yoav Gallant</strong>, amid a crisis of trust over differences in managing <a href="https://www.benzinga.com/topic/israel-hamas-war">Israel's war efforts in Gaza</a>.</p>
<p>Gallant, who had held the defense minister post since 2022, has been a key figure in Israel&#8217;s response to the ongoing conflicts against Hamas and Iran-backed Hezbollah. </p>
<p>According to Netanyahu&#8217;s remarks, the relationship between the two deteriorated in recent months, fueled by what the prime minister described as significant gaps in their approach to the war effort.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/24/10/41348633/emmanuel-macron-has-sharp-words-for-israels-pm-mr-netanyahu-must-not-forget-that-his-country-was-cre">Emmanuel Macron Has Sharp Words For Israel&#8217;s PM: &#8216;Mr. Netanyahu Must Not Forget That His Country Was Created By A UN Decision&#8217;</a></strong></p>
<p>"I tried to bridge these gaps, but they kept getting wider," Netanyahu said in a statement. He argued that the trust issues had become "public domain," a development that he claimed was exploited by Israel's adversaries. </p>
<p>Gallant, for his part, responded to the firing on X, formerly known as Twitter. He expressed unwavering commitment to Israel's safety.</p>
<p>"The security of the State of Israel was and will always remain the mission of my life," he wrote.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="iw" dir="rtl">ביטחון מדינת ישראל היה ותמיד יישאר משימת חיי &#x1f1ee;&#x1f1f1;&#x1f1ee;&#x1f1f1;</p>
<p>&mdash; יואב גלנט &#8211; Yoav Gallant (@yoavgallant) <a href="https://twitter.com/yoavgallant/status/1853862189888602366?ref_src=twsrc%5Etfw">November 5, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>In place of Gallant, Netanyahu has appointed <strong>Israel Katz</strong>, a seasoned politician who has held multiple cabinet positions, including minister of foreign affairs, minister of finance, and minister of intelligence.</p>
<p>&#8220;He is known as a bulldozer with a combination of responsibility and firmness, quiet firmness, and all of these are very important for managing the campaign,&#8221; Netanyahu said about Katz.</p>
<p>Additionally, Netanyahu revealed discussions with minister without portfolio Gideon Sa'ar, inviting him to join the coalition as Foreign Minister.</p>
<h3 class="wp-block-heading">Market Reactions: Oil, Israeli Stocks Rise</h3>
<p>News of Gallant's dismissal and the internal discord in Israel's wartime leadership had a marginal impact on financial markets, with traders fully focused on the upcoming results from U.S. elections. </p>
<p>West Texas Intermediate (WTI) light crude, tracked by the <strong>United States Oil Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), was 0.6% up to $72.2 a barrel as of 3:10 p.m. ET on Tuesday, holding earlier gains during the session and marking its second consecutive day in the green.</p>
<p>Israeli stocks saw a slight boost Tuesday, with the <strong>VanEck Israel ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>) climbing 0.8%.</p>
<p><strong>Now Read</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41753325/wall-street-rallies-on-election-day-palantir-skyrockets-bitcoin-tops-70-000-whats-driving-">Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What&#8217;s Driving Markets Tuesday?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Emerging Markets

Emerging Market ETFs

Commodities

Politics

ETFs

ISRA

Israel's Netanyahu Fires Defense Minister Gallant Over Lack Of Trust in War Management, Oil Prices Rise As Election Results Loom

<p><strong>MariMed</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that MariMed will report an <strong>earnings per share</strong> (EPS) of $-0.01. </p>
<p>MariMed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 3.43% increase in the share price the following trading session.</p>
<p>Here's a look at MariMed's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.01</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>0</td>
<td>0.004</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840556_0.png" alt="eps graph" /></p>
<h3>Performance of MariMed Shares</h3>
<p>Shares of MariMed were trading at $0.1629 as of November 04. Over the last 52-week period, shares are down 49.97%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MRMD/earnings"><strong>To track all earnings releases for MariMed visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MRMD

Exploring MariMed's Earnings Expectations

<p>Stewart Information Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STC#NYSE">STC</a>) will release its quarterly earnings report on Wednesday, 2024-10-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Stewart Information Servs to report an <strong>earnings per share</strong> (EPS) of $1.04.</p>
<p>The market awaits Stewart Information Servs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.22, which was followed by a 1.13% drop in the share price the next day.</p>
<p>Here's a look at Stewart Information Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.04</td>
<td>1.13</td>
<td>-0.13</td>
<td>0.53</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.17</td>
<td>0.91</td>
<td>0.17</td>
<td>0.60</td>
<td>0.86</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840549_0.png" alt="eps graph" /></p>
<h3>Market Performance of Stewart Information Servs's Stock</h3>
<p>Shares of Stewart Information Servs were trading at $67.63 as of November 04. Over the last 52-week period, shares are up 53.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Stewart Information Servs</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Stewart Information Servs.</p>
<p>With 1 analyst ratings, Stewart Information Servs has a consensus rating of Neutral. The average one-year price target is $75.0, indicating a potential 10.9% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and Trupanion, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Trupanion, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trupanion</td>
<td>Neutral</td>
<td>14.55%</td>
<td>$49.38M</td>
<td>0.46%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Stewart Information Servs ranks in the middle among peers for Revenue Growth and Gross Profit, with a growth rate of 14.55% and gross profit of $49.38M. However, it lags behind in terms of Return on Equity, standing at 0.46%. The consensus rating for the company is neutral.</p>
<h3>About Stewart Information Servs</h3>
<p>Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.</p>
<h3>Unraveling the Financial Story of Stewart Information Servs</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Stewart Information Servs showcased positive performance, achieving a revenue growth rate of <strong>10.91%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Stewart Information Servs's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.51%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Stewart Information Servs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.17%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Stewart Information Servs's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.12%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.4</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/STC/earnings"><strong>To track all earnings releases for Stewart Information Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Stewart Information Servs's Earnings Outlook

<p>Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Granite Point Mortgage to report an <strong>earnings per share</strong> (EPS) of $-0.82.</p>
<p>Anticipation surrounds Granite Point Mortgage's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.16, which was followed by a 4.46% drop in the share price the next day.</p>
<p>Here's a look at Granite Point Mortgage's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.21</td>
<td>0.02</td>
<td>-0.29</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>0.03</td>
<td>0.14</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840537_0.png" alt="eps graph" /></p>
<h3>Market Performance of Granite Point Mortgage's Stock</h3>
<p>Shares of Granite Point Mortgage were trading at $3.01 as of November 04. Over the last 52-week period, shares are down 35.43%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GPMT/earnings"><strong>To track all earnings releases for Granite Point Mortgage visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GPMT

Granite Point Mortgage's Earnings: A Preview

<p><strong>Tutor Perini</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tutor Perini will report an <strong>earnings per share</strong> (EPS) of $-1.89. </p>
<p>The market awaits Tutor Perini's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 26.81% drop in the share price the following trading session.</p>
<p>Here's a look at Tutor Perini's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.19</td>
<td>-0.17</td>
<td>0.13</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.19</td>
<td>0.30</td>
<td>-0.91</td>
<td>-0.71</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-27.0%</td>
<td>28.000000000000004%</td>
<td>23.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840530_0.png" alt="eps graph" /></p>
<h3>Performance of Tutor Perini Shares</h3>
<p>Shares of Tutor Perini were trading at $26.14 as of November 04. Over the last 52-week period, shares are up 261.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TPC/earnings"><strong>To track all earnings releases for Tutor Perini visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Tutor Perini Earnings Preview

<p>Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Finance of America to report an <strong>earnings per share</strong> (EPS) of $0.09.</p>
<p>Finance of America bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.15, leading to a 0.97% drop in the share price on the subsequent day.</p>
<p>Here's a look at Finance of America's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.20</td>
<td>-0.6</td>
<td>-0.8</td>
<td>-0.3</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>-0.3</td>
<td>-0.9</td>
<td>-1.1</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>-28.000000000000004%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840523_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Finance of America were trading at $12.85 as of November 04. Over the last 52-week period, shares are up 86.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FOA/earnings"><strong>To track all earnings releases for Finance of America visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


An Overview of Finance of America's Earnings

<p>Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 3.7 percent. This is a 9.68 percent decrease over earnings of $0.31 per share from the same period last year.  The company reported quarterly sales of $1.11 billion which beat the analyst consensus estimate of $1.10 billion by 0.73 percent.  This is a 10.37 percent increase over sales of $1.00 billion the same period last year.</p>


Grocery Outlet Holding Q3 Adj $0.28 Beats $0.27 Estimate, Sales $1.11B Beat $1.10B Estimate

<p>Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.08) by 150 percent.  The company reported quarterly sales of $204.431 million which beat the analyst consensus estimate of $181.772 million by 12.47 percent.  This is a 12.95 percent increase over sales of $180.991 million the same period last year.</p>


MRCY

Mercury Sys Q1 2025 Adj. EPS $0.04 Beats $(0.08) Estimate, Sales $204.431M Beat $181.772M Estimate

<p>Across the recent three months, 5 analysts have shared their insights on Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.2, a high estimate of $37.00, and a low estimate of $26.00. This upward trend is evident, with the current average reflecting a 1.9% increase from the previous average price target of $31.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840515_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Teradata by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Austin Dietz</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Chirag Ved</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teradata. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teradata compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Teradata's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teradata analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Teradata</h2>
<p>Teradata Corp provides analytic data products and related services. The Company operates in data and analytics, which captures, integrates, stores, manages, and analyzes data of all types to answer business questions and deliver insight; and marketing applications, which offer marketing management products to help businesses win customer loyalty. Its solutions include components such as data warehousing, Asset optimization, Fraud prevention, Product innovation, and risk mitigation. A majority of the firm's revenue is generated in the United States.</p>
<h3>Teradata's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Teradata's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-5.63%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Teradata's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.49%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>57.36%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.2%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Teradata's debt-to-equity ratio surpasses industry norms, standing at <strong>8.13</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Breaking Down Teradata: 5 Analysts Share Their Views

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>For many people, the most important thing about investing is knowing which stocks to buy, and when to buy them. If you&rsquo;re a buy-and-hold investor, then you&rsquo;re going to keep your picks for a long time. If you&rsquo;re a more active trader, then you&rsquo;re also looking for the perfect time to take your profits and move on. </p>



<p>It&rsquo;s critically important for any investor to also be able to recognize which stocks to avoid &ndash; because those are the stocks that will wreck your portfolio if given the chance.</p>



<p>This has been an interesting year in the market so far. <a href="https://investorplace.com/industries/technology/">Tech stocks</a> are continuing to rule the day, with the tech-heavy <strong>Nasdaq composite</strong> up nearly 10% on the year. The <strong>S&amp;P 500</strong> is doing well as well, up 7%. Meanwhile, the benchmark <strong>Dow Jones Industrial Average</strong> shows only a 2% gain for the year.</p>



<p>With those kinds of gains on the table, it would be tragic to bury your money into F-rated stocks. The &ldquo;F&rdquo; rating comes from the Portfolio Grader &ndash; a free service that evaluates stocks on an &ldquo;A&rdquo; through &ldquo;F&rdquo; scale based on growth, earnings performance, analyst sentiment and trading momentum.</p>



<p>No tool is infallible, but I&rsquo;ve found the Portfolio Grader to be an ideal system to help investors of all stripes ferret out which stocks are worth your attention and which ones are stocks to avoid. The names on this list definitely fall within the latter category.</p>



<h2>Lucid Motors (LCID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/cciv-stock-2-300x169.jpg" alt="The Lucid Motors (LCID) Plant in Arizona."><div>Source: Around the World Photos / Shutterstock.com</div></div><p>It&rsquo;s an easy choice to kick off any list of stocks to avoid with the struggling electric vehicle company <strong>Lucid Motors</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lcid-stock-quote/"><strong>LCID</strong></a>). Once thought to be a legitimate rival to <strong>Tesla</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/"><strong>TSLA</strong></a>), Lucid has failed to scale its business and is a major disappointment.</p>



<p>How can any company be considered a possible Tesla killer when it only produced 6,001 vehicles last year? In the first quarter of this year, Lucid manufactured another 1,728 vehicles and delivered 1,967.</p>



<p>Bulls will point out that Lucid managed to beat expectations for revenue in the first quarter, bringing in $173 million versus the expected $154 million. But that was only because of Lucid&rsquo; vehicle sales to the <a href="https://www.barrons.com/articles/lucid-earnings-stock-price-suv-8f036253">Saudi Arabian government</a>. When you look at external customers, demand for Lucid vehicles is falling. (Saudi Arabia&rsquo;s <strong>Public Investment Fund</strong> has a 60% stake in Lucid.)</p>



<p>LCID stock is down 32% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Akoustis Technologies (AKTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/down-arrow-coins-stocks-sell-1600-300x169.jpg" alt="Photo of stair of coins with red arrow headed downward over top of the coin stacks"><div>Source: shutterstock.com/Pla2na</div></div><p><strong>Akoustis Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/"><strong>AKTS</strong></a>) is a North Carolina company that designs, develops, manufactures and sells radio frequency filter products. It operates a 125,000-square-foot wafer manufacturing facility in New York to design and build filters and other semiconductor devices.</p>



<p>But its most recent earnings report was a major disappointment. Revenue in the third fiscal quarter of 2024 was $7.51 million, up 2.1% from a year ago, but missed analyst estimates by 12%.</p>



<p>The company posted a net loss of $23.3 million, which was a 50% increase from a year ago, and lost 26 cents per share versus a loss of 23 cents per share a year ago. The EPS mark was particularly disappointing, as it missed analysts&rsquo; estimates by 86%.</p>



<p>The quarter ended with Akoustis having only <a href="https://ir.akoustis.com/news-events/press-releases/detail/355/akoustis-reports-third-quarter-fy24-results">$15.2 million on cash on hand</a> and assets of $28.5 million, down from $43.1 million in cash and total assets of $59.8 million a year ago. So is no surprise that Akoustis is now selling an additional <a href="https://ir.akoustis.com/news-events/press-releases/detail/357/akoustis-announces-10-million-registered-direct-offering">50 million shares of stock</a>, priced at 20 cents per share, in an effort to raise $10 million to fund operations.</p>



<p>AKTS stock is down 79% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Verastem (VSTM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div><p><strong>Verastem</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/"><strong>VSTM</strong></a>) is a biopharmaceutical company that is working on treatments for cancer. The company is focused specifically on RAS pathway-driven cancers and is developing treatments targeted toward mutated RAS genes.</p>



<p>Verastem is seeking FDA approval for avutometinib and defactinib combination for patients with recurrent KRAS gene mutant low-grade serous ovarian cancer. The rolling review process allows the company to submit completed sections of an application for FDA review before all sections are available.</p>



<p>While this could be a great breakthrough for patients, investors would be wise to be cautious. Clinical trials and FDA approval are costly, time-consuming, and sometimes yield no results. Developing a breakthrough drug can lead to highly profitable rewards.</p>



<p>Verastem has $110.1 million in cash at the end of the first quarter, having losing $33.9 million in the period. Research and development costs were $17.7 million, and selling, general and administrative expenses were $10.4 million.</p>



<p>The company is investing more in preparation for a potential launch of avutometinib and defactinib treatment. The stock price dropped 59% when it announced its FDA approval plans. </p>



<p>Once trading as high as $14 per share, VSTM stock is down to penny stock territory now, having lost 56% in value so far on the year. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/muln1600-2-300x169.png" alt="In this photo illustration, the Mullen Technologies (MULN) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div><p><strong>Mullen Automotive</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/"><strong>MULN</strong></a>) is another struggling electric vehicle company. </p>



<p>Like Lucid, it had high expectations that it would challenge Tesla, and its encountered similar issues with trying to scale the business to make a dent in the EV field.</p>



<p>Mullen had a wild 2023 just trying to stay relevant. On three separate occasions it triggered a reverse stock split to keep the stock price over $1 per share and maintain Nasdaq compliance. The last of those splits was a 1-for-100 split that on paper pushed the stock price higher. But in reality, the value of Mullen shares fell by 99% over the course of the year.</p>



<p>Mullen&rsquo;s strategy is now to go into commercial EVs. Its expanding its distribution network into&nbsp;<a href="https://finance.yahoo.com/news/mullen-announces-european-distributor-gama-130000336.html">Eastern Europe</a>&nbsp;and it signed a new deal to supply 40 commercial vehicles to a company in&nbsp;<a href="https://finance.yahoo.com/news/mullen-automotive-secures-major-european-183010622.html">Switzerland</a>. Mullen also completed the first phase of its&nbsp;<a href="https://investorplace.com/2024/04/muln-stock-alert-mullen-hits-new-battery-pack-milestone/">battery line integration</a>&nbsp;at its California plant in hopes of commercializing EV battery packs.</p>



<p>While it finally saw some revenue in the second quarter of fiscal 2024 &mdash; $33,000 &ndash; it also saw losses of $177.3 million. And now with only $22.3 million in cash and cash equivalents left, Mullen will need to find more funding if it&rsquo;s going to keep up this level of cash burn.</p>



<p>MULN stock is down 73% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Takeda Pharmaceutical (TAK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p><strong>Takeda Pharmaceutical</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/tak-stock-quote/"><strong>TAK</strong></a>) is a Japanese pharmaceutical company that has a large presence in the U.S. as well. The company traces its roots back to the 18th century and currently operates in 80 countries.</p>



<p>Its top-selling drug is Entyvio, which treats patients with ulcerative colitis and Crohn&rsquo;s disease. Revenues in 2022 for Entyvio were $4.5 billion.</p>



<p>It also makes Vynanse, which is a popular drug for attention deficit disorder. But it lost exclusivity for the drug in 2023 and generic competitors are now on the market.</p>



<p><a href="https://assets-dam.takeda.com/image/upload/v1715231595/Global/Investor/Financial-Results/FY2023/Q4/q4_fy2023_press_release_en.pdf">Earnings for 2023</a> were 4.26 trillion yen, ($272.6 billion), up 5.9% from a year ago. But net profit was 144 billion yen and EPS was 92 billion yen, both down 54% from a year ago.</p>



<p>Takeda forecast 2024 revenue of 4.35 trillion yen, with core revenue flat to slightly declining. It also forecast a 10% decline in operating profit and an EPS decline in the mid-10%.</p>



<p>TAK stock is down 6% this year but doesn&rsquo;t have a strong growth story for 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Cue Health (HLTH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600d-300x169.jpg" alt="Healthcare professional in green scrubs standing with arms crossed."><div>Source: Shutterstock</div></div><p><strong>Cue Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/"><strong>HLTH</strong></a>) is a tiny health care company with a market capitalization of only $9 million. The San Diego-based company provides a platform that provides patients and health care workers with access to lab-quality diagnostic tests at home and in a doctor&rsquo;s office.</p>



<p>Its Covid-19 test was the first home use respiratory tests to get approval from the FDA.</p>



<p>Unfortunately for Cue, people aren&rsquo;t testing for Covid-19 in 2024 at the same frequency they were in the last few years. In addition, Cue received a <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cue-health-inc-675673-05092024">warning letter</a> in May from the FDA about its home Covid-19 tests. </p>



<p>The letter alleged that the company made changes to the test without approval from the government oversight agency. The FDA issued a <a href="https://www.fda.gov/medical-devices/safety-communications/do-not-use-cue-healths-covid-19-tests-due-risk-false-results-fda-safety-communication">public statement</a> saying not to use the Cue test because it could issue a false result.</p>



<p>Cue says it&rsquo;s evaluating the letter but has not made a further comment. It was scheduled to issue its first-quarter earnings report on May 13 but has not done so.</p>



<p>HLTH stock is down 62% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Blue Star Foods (BSFC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/sell-thumbs-down-one-300x169.jpg" alt="a businessman with his thumb facing down"><div>Source: Shutterstock</div></div><p><strong>Blue Star Foods</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/"><strong>BSFC</strong></a>) is a Miami-based seafood company. It imports, packages and sells crab meat and salmon in many major grocery stores throughout the U.S.</p>



<p>But with a limited product base, Blue Star has some inherent risks. The population of crab can fluctuate because of disease or biological issues. Market demand can also factor into Blue Star earnings. In addition, the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=102213&amp;ref=318207335&amp;type=PDF&amp;symbol=BSFC&amp;cdn=1ddbb1099d22575dbc67179b9c4d79de&amp;companyName=Blue+Star+Foods+Corp.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-01">worldwide supply of natural fish is dropping</a> and causing many countries to limit the amount of seafood that can be caught and harvested.</p>



<p>Blue Star had revenue of $2.3 million in the first quarter, up from $1.9 million a year ago. The net loss was $1.1 million, from a loss of $2 million in the same quarter a year ago.</p>



<p>Blue Star, which recently executed a reverse 1-for-50 stock split to keep its stock price in compliance with Nasdaq listing rules, is down 68% this year. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<p><em>On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/">7 F-Rated Stocks to Avoid at All Costs in June</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 F-Rated Stocks to Avoid at All Costs in June

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Steer clear of stocks to avoid in order to effectively protect your investment portfolio.</p>



<p>Moreover, the essence of investing is identifying the next high-flying stock and knowing which stocks to avoid. Additionally, in the past year, we&rsquo;ve seen how investors have rushed into stocks with overstretched valuations in the fear of missing out. Also, several investors have tried to catch the next big AI penny stock, only to catch falling knives instead.</p>



<p>Keeping that in mind, you should prune the following three stocks from your portfolio.</p>



<h2>Lucid Group (LCID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/lcid1600-1-300x169.png" alt="Lucid Air car of Lucid Automotive (LCID) Manufacturer at the event, EV Lucid Car Showroom."><div>Source: Khosro / Shutterstock.com</div></div><p>Once a promising player in the hotly competitive Chinese EV space, <strong>Lucid Group</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lcid-stock-quote/"><strong>LCID</strong></a></span>) languishes in penny stock territory. LCID stock is trading more than 95% below its all-time high of $58.05 in February 2021. Moreover, it continues to get hammered by the stock market due to deplorable sales and a relentless cash burn.</p>



<p>Unlike most of its competition, though, Lucid&rsquo;s survival hinges on the dilutive yet critical cash infusions from Saudi Arabia&rsquo;s Public Investment Fund (<strong>PIF</strong>). However, such a strategy is unlikely to bear fruit as Lucid struggles to find its feet in the EV space. Additionally, its cash reserves <a href="https://seekingalpha.com/symbol/LCID/balance-sheet">have dropped roughly 65%</a> from their 2021 balance of $6.26 billion.</p>



<p>In recent news, the company <a href="https://seekingalpha.com/news/4110179-lucid-group-lays-off-6-of-its-workforce-as-part-of-a-restructuring-plan?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A4">laid off 6% of its workforce</a> to control the bleeding. Nevertheless, forward estimates suggest that the company will remain in the red this year and the next. Hence, with the broader market slowdown in mind, LCID is arguably the worst EV stock bet at this point.</p>



<h2>Peloton Interactive (PTON)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/pton1600-300x169.jpg" alt="Peloton (PTON stock) sign on city storefront. Peloton layoffs"><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Peloton Interactive</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pton-stock-quote/"><strong>PTON</strong></a></span>), once the crown jewel of pandemic fitness, is now struggling to survive in the post-pandemic slump. </p>



<p>With people favoring gym sessions instead of home workouts, Peloton Interactive&rsquo;s connected exercise equipment has fallen completely out of favor. It&rsquo;s up against multiple headwinds, including stiff competition, the economic slowdown and operational hurdles.</p>



<p>The company hasn&rsquo;t turned a profit since December 2020 and is unlikely to do so in the near future. Additionally, multiple safety recalls, including the most recent one in May, recalled two million bikes. Also, the firm has <a href="https://www.cnbc.com/2024/05/02/peloton-ceo-barry-mccarthy-steps-down-15percent-of-staff-laid-off.html">slashed 15% of its workforce</a> and seen its Chief Executive Officer (<strong>CEO</strong>) depart, part of its belt-tightening efforts.</p>



<p>Despite these measures, analysts forecast that despite aggressive cost-cutting measures and strategic overhauls, Peloton Interactive is likely to continue posting losses for the foreseeable future. PTON stock dipped <a href="https://seekingalpha.com/symbol/PTON/momentum/performance">more than 50% last year</a> and north of 40% year-to-date (<strong>YTD</strong>), offering limited upside potential for investors.</p>



<h2>Akoustis Technologies (AKTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/warning-alarm-sounding-signal-1600-300x169.jpg" alt="Photo of alarm tower with speakers against blue sky, representing warning"><div>Source: shutterstock.com/jakkapan</div></div><p>North Carolina-based <strong>Akoustis Technologies</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/akts-stock-quote/"><strong>AKTS</strong></a></span>) develops sophisticated radio frequency filter products. </p>



<p>Despite operating a high-growth business over the years, it has witnessed a dramatic slowdown in recent quarters. It has missed top-line estimates by considerable margins in five of the past six quarters. Additionally, it has missed earnings estimates in the past four quarters. Consequently, the stock is <a href="https://seekingalpha.com/symbol/AKTS/momentum/performance">down more than 70% YTD</a>, following up on its dismal showing last year, when it lost 95%.</p>



<p>Moreover, this shortfall reflects deeper financial woes, indicated by a 50% jump in net losses to $23.3 million and a disappointing earnings per share (<strong>EPS</strong>) deficit of 26 cents. Furthermore, the firm&rsquo;s cash till and short-term assets base has dropped a substantial 65% from June last year, <a href="https://seekingalpha.com/symbol/AKTS/balance-sheet">currently at just $15.2 million in cash</a>. &nbsp;Additionally, to stay afloat, it recently issued 50 million shares at a mere 20 cents each, aiming to gather $10 million for its working capital needs.</p>



<p><em>On the&nbsp;date of publication, Muslim Farooque did not have (either&nbsp;directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em></p>
<div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/3-stocks-no-one-in-their-right-mind-would-own-right-now-june-edition/">3 Stocks No One in Their Right Mind Would Own Right Now: June Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Stocks No One in Their Right Mind Would Own Right Now: June Edition

In a report released today, Anthony Stoss from Craig-Hallum maintained a Hold rating on Akoustis Technologies (AKTS – Research Report). The company...

Akoustis Technologies (AKTS) Gets a Hold from Craig-Hallum

Akoustis secures $8M in volume XBAW orders with Tier-1 customer

Craig-Hallum analyst Anthony Stoss maintained a Hold rating on Akoustis Technologies (AKTS – Research Report) today. The company's shares opened to...

Akoustis Technologies (AKTS) Receives a Hold from Craig-Hallum

An update from Akoustis Technologies (AKTS) is now available. David M. Aichele, Executive Vice President of Business Development at Akoustis Techno...

Akoustis Technologies Announces Executive Leadership Changes

Akoustis Technologies CEO Jeffery Shealy resigns

Akoustis Technologies (AKTS) has shared an update. Akoustis Technologies, Inc. has experienced significant executive and board member changes, with...

Akoustis Technologies Overhauls Leadership and Board

Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more

Akoustis Technologies ( ($AKTS) ) has issued an update. Akoustis Technologies, Inc. has appointed Kamran Cheema to its Board of Directors for a ter...

Akoustis Technologies Names Kamran Cheema CEO and Director

ADSK

AFRM

AKTS

ALPP

AMBA

ATHE

BBWI

BSFC

BURL

BZUN

CANF

CHWY

CRWD

DELL

DOMO

ESTC

GOTU

HAIN

HLTH

LCID

LILM

LULU

MRVL

MULN

NCNO

NNVC

NTAP

NTNX

NVDA

OKTA

OLLI

PLCE

PSTG

PTON

SMTC

SSYS

TCOM

TIGR

TSLA

UAVS

ULTA

VEEV

VSCO

VSTM

Press Releases

Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET

Akoustis Reports Third Quarter FY24 Results

Akoustis Completes Rollout of its XBAW® Design Updates

Akoustis Announces $10 Million Registered Direct Offering  Priced At-The-Market Under Nasdaq Rules

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

Akoustis Receives $2 Million in Volume Orders for Wi-Fi 7 Program from Tier-1 Carrier

Akoustis Secures $8 Million in Volume XBAW® Orders with Tier-1 Customer

Akoustis Announces Leadership Transition

Akoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 Customer

Comments

Akoustis Technologies

Notizie

Ultime notizie per Akoustis Technologies (NASDAQ:AKTS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO